Ravuconazole in Preventing Fungal Infections in Patients Undergoing Allogeneic Stem Cell Transplantation

PHASE1/PHASE2CompletedINTERVENTIONAL

Timeline

Start Date

June 30, 2003

Study Completion Date

September 30, 2004

Conditions

Breast CancerChronic Myeloproliferative DisordersGestational Trophoblastic TumorInfectionLeukemiaLymphomaMultiple Myeloma and Plasma Cell NeoplasmMyelodysplastic SyndromesMyelodysplastic/Myeloproliferative NeoplasmsNeuroblastomaOvarian CancerTesticular Germ Cell Tumor

Interventions

DRUG

ravuconazole

Trial Locations (1)

20892-1182

Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

National Institutes of Health Clinical Center (CC)

NIH

NCT00064311 - Ravuconazole in Preventing Fungal Infections in Patients Undergoing Allogeneic Stem Cell Transplantation | Biotech Hunter | Biotech Hunter